2025/04/29
We are proud to announce the closure of an oversubscribed Pre-Series A funding round, backed by leading investors including HEMEX, Zürcher Kantonalbank, Excellis, EFI Lake Geneva Ventures, and Club degli Investitori.
With this support—alongside ongoing funding from Horizon Europe and Innosuisse—Annaida is accelerating the development of its pioneering Micro-MRS technology, bringing new possibilities to science and medicine.
2024/12/31
Our patent N.2019800771876 for a ‘Miniaturized Magnetic Resonance Device’ has been granted in China too, following granting in EU and Japan.
Patent details
2024/04/01
The HyperCell project will focus on the optimization, integration and validation of NVISION’s Quantum-Based Platform, which Enhances NMR spectrometers’ sensitivity to metabolites via hyperpolarization, enabling real-time monitoring of intracellular metabolic activity, with ANNAIDA’s Embryospin Sensor Technology Tailored for microscale NMR.
*Grant agreement ID: 101158959
If you like a quote or just some more information we would love to hear from you.
We are constantly looking for ways to expand the ecosystem and work with more companies and researchers.
Please fill in the form below and we will be in touch soon.
Address (PO box)
Annaida Technologies SA
Innovation Park-C
1015, Lausanne, Switzerland
E-mails
marco.grisi@annaida.ch
